profit from every $100 of sales.
$0$100
Warby Parker
$27.44+2.66% today
+60.0% in 1 year
1-year low $17.011-year high $30.34
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $2,078.73 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Warby Parker sold, what it kept, and what it did with the cash.
Sales went from $598 million in 2022 to $872 million in 2025, with $1.64 million of profit last year.
SalesProfit
Warby Parker vs. similar companies
Warby Parker grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Warby Parker | 2,078.7× · Very expensive | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.8× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads Warby Parker's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 598 | 670 | 771 | 872 | |
| 341 | 365 | 427 | 471 | |
| -111 | -72 | -30 | -5 | |
| -79 | -33 | 16 | 45 | |
| -110 | -63 | -20 | 2 | |
| -0.96 | -0.54 | -0.17 | 0.01 | |
| 57.0% | 54.5% | 55.3% | 54.0% | |
| -18.6% | -10.7% | -3.9% | -0.6% | |
| -18.5% | -9.4% | -2.6% | 0.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 569 | 580 | 676 | 721 |
| Cash | 209 | 217 | 254 | 286 |
| Total debt | 173 | 174 | 225 | 233 |
| Total liabilities | 282 | 279 | 336 | 353 |
| 287 | 302 | 340 | 368 | |
| 115 | 117 | 120 | 123 | |
| -19.1% | -11.9% | -4.2% | -0.7% | |
| -38.5% | -20.9% | -6.0% | 0.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 10 | 61 | 99 | 111 | |
| 60 | 54 | 64 | 67 | |
| -50 | 7 | 35 | 44 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | – | – | |
| 98 | 71 | 47 | 35 |
Valuation
- 2,078.7×
- 57.6×
- –
- 9.3×
- 3.9×
- 78.0×
- 74.7×
- 1.3%
- 0.0%
- 0.0%
Profitability
- 54.0%
- -0.6%
- 0.2%
- 4.0%
- -0.6%
- -18.2%
- 0.4%
- 0.2%
- -1.1%
- –
Growth
- +13.4%
- –
- +26.0%
- –
- +1.9%
Financial health
- -1.4×
- 0.63
- 32.3%
- –
- 2.33
- 2.03
- 1.21
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 32%of 952
Bottom 20%of 884
Top 41%of 886
Top 50%of 987
What analysts expect
- Average price target
- $29.33
- Range
- $20.00 – $35.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.12 | 0.11 | +9.1% |
| Feb 26, 2026 | -0.04 | 0.05 | −180.0% |
| Nov 6, 2025 | 0.11 | 0.09 | +22.2% |
| Aug 7, 2025 | 0.08 | 0.08 | +0.0% |
| May 8, 2025 | 0.12 | 0.12 | +0.0% |
| Feb 27, 2025 | 0.01 | 0.03 | −66.7% |
| Nov 7, 2024 | 0.05 | 0.05 | +0.0% |
| Aug 8, 2024 | 0.06 | 0.05 | +20.0% |
News
Why Warby Parker Stock Popped TodayYahoo Finance · Nov 6, 2026Warby Parker GAAP EPS of $0.04 beats by $0.01, revenue of $244.7M in-lineSeeking Alpha · Nov 5, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
30No pass
Philip Fisher
43No pass
Peter Lynch
51No pass
Joel Greenblatt
0No pass
Charlie Munger
33No pass
Terry Smith
37No pass
Questions about Warby Parker
Is Warby Parker a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Warby Parker AI analysis
What does Warby Parker do?
Warby Parker Inc. provides eyewear products. It offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, and contact lenses, as well as accessories, including cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray. It is in Medical - Instruments & Supplies, based in New York, NY, United States, with 2,275 employees.
Does Warby Parker pay a dividend?
No. Warby Parker does not pay a dividend at the moment.
Is Warby Parker stock halal?
Yes. Warby Parker passes our halal screen: its business is permitted and its debt is 7% of its market value, under the 30% limit. How we check
How has Warby Parker stock done over the past year?
Up 60.0% over the past twelve months, to $27.44. It traded between $17.01 and $30.34 and is 9.6% below its high.
Who are Warby Parker's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with Warby Parker's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.